Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive ...

Despite Halozyme reporting generally positive first-quarter results, the stock was negatively impacted by the potential risk that its hyaluronidase combination products may face earlier price ...

The annual inflation rate in the US slowed to 2.3% in April from 2.4% in the previous month and versus market estimates of ...

FacebookTweetPin AI and growth stocks in general have continued extending their gains so far today after the CPI report ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Biggest stock gainers. Coinbase (NASDAQ:COIN) +11% — Shares jumped after S&P Dow Jones Indices announced the crypto exchange ...

We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look ...

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take ...

Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an ...